Clinical Pipeline

Our partners are advancing several compounds in clinical trials that were the outcome of previous drug discovery collaborations with Astex including three drugs that have now been approved. The responsibility for developing these products is with our partners.

DiscoveryPhase 1Phase 2Phase 3Marketed

Kisqali® (ribociclib)

CDK4/6 inhibitor (Oncology)
Partner: Novartis

.....

Balversa® (erdafitinib)

FGFr inhibitor (Oncology)
Partner: Janssen

.....

Truqap® (capivasertib)

PKB/Akt Inhibitor (Oncology)
Partner: AstraZeneca

.....

KRAS Oncogene (Oncology)

Partner: MSD and Taiho

G12C:

....

Other mutants:

.

Beroterkib (ASTX029)

Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
Partner: Mosaic Therapeutics

...

ASTX295

Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
Partner: Mosaic Therapeutics

..

SHP2 (Oncology)

Partner: MSD and Taiho

..

P53 (Oncology)

Partner: MSD

.